Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
TNYA
TNYA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TNYA News
Tenaya Therapeutics Plans 2026 Data Release for Heart Disease Gene Therapies
Jan 09 2026
Globenewswire
Tenaya Shares Drop Following $60 Million Equity Raise
Dec 12 2025
Benzinga
S&P 500 Declines 1%; Broadcom Reports Earnings Exceeding Expectations
Dec 12 2025
Benzinga
Dow Gains More Than 100 Points as Lululemon Reports Strong Q3 Earnings
Dec 12 2025
Benzinga
Tenaya Therapeutics Sets $60 Million Price for 50 Million Unit Offering, Clinical Hold on TN-201 Rescinded
Dec 12 2025
NASDAQ.COM
Tenaya Therapeutics Sets Price for $60 Million Unit Offering
Dec 12 2025
Yahoo Finance
Tenaya Therapeutics Prices $60 Million Public Offering
Dec 12 2025
Newsfilter
Tenaya Therapeutics Prices $60 Million Public Offering of 50 Million Units
Dec 12 2025
Globenewswire
Tenaya Therapeutics Reveals Pricing for Public Offering
Dec 12 2025
Yahoo Finance
Tenaya Therapeutics Plans to Offer Common Stock and Warrants
Dec 11 2025
Globenewswire
Tenaya Therapeutics Unveils Encouraging Interim Results from MYPEAK™-1 Phase 1b/2a Trial of TN-201 Gene Therapy for MYBPC3-Related Hypertrophic Cardiomyopathy
Nov 08 2025
Newsfilter
Tenaya Therapeutics Shares Decline Following FDA's Clinical Hold on Heart Disorder Study
Nov 07 2025
SeekingAlpha
Tenaya Therapeutics to Present New Clinical Data on TN-201 Gene Therapy in Late-Breaking Session at the 2025 American Heart Association Scientific Sessions
Nov 04 2025
Newsfilter
Tenaya Therapeutics to Attend Investor Conferences This October
Oct 02 2025
Newsfilter
"Four Biotech Stocks Poised for Breakout as Momentum Scores Rise"
Sep 08 2025
Benzinga
HC Wainwright & Co. Affirms Buy Rating for Tenaya Therapeutics, Keeps $5 Price Target Intact
Sep 02 2025
Benzinga
Show More News
